Mela Sciences (MELA) +111% after an FDA panel narrowly backed its experimental skin cancer detection device late Thursday. Some panelists said MELA's MelaFind device could help save lives, while others expressed doubts that it could help doctors detect cancers. Earlier this week, FDA staffers said MelaFind was not studied adequately, could be a health risk, and urged a new clinical study.